omega-3 ethylester concentrate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 171 Diseases   26 Trials   26 Trials   2441 News 


«12345678910111213...2021»
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Biomarker, Enrollment change, Trial withdrawal:  Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury (clinicaltrials.gov) -  Oct 13, 2022   
    P2,  N=0, Withdrawn, 
    Recruiting --> Active, not recruiting | N=34 --> 21 N=45 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Enrollment closed, Trial primary completion date:  ALTA: Altering Lipids for Tolerance of Aromatase Inhibitor Therapy (clinicaltrials.gov) -  Oct 7, 2022   
    P2,  N=77, Active, not recruiting, 
    N=45 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2023 --> Nov 2022
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Enrollment open, Trial initiation date:  Immunonutrition for Diabetic Foot Ulcers (clinicaltrials.gov) -  Sep 29, 2022   
    P2/3,  N=30, Enrolling by invitation, 
    Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> Aug 2022 Not yet recruiting --> Enrolling by invitation | Initiation date: Jun 2022 --> Oct 2022
  • ||||||||||  Journal:  Lipid-lowering drugs. (Pubmed Central) -  Sep 20, 2022   
    Not yet recruiting --> Enrolling by invitation | Initiation date: Jun 2022 --> Oct 2022 No abstract available
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Successful Treatment of PEG-Asparaginase Related Hypertriglyceridemia with Omega-3 Acid Ethyl Esters () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_2204;    
    In the case of our patient, we used a prolonged course of fish oil for the treatment of elevated triglyceride levels. Fish oil allowed our patient to continue treatment with a PEG-asparaginase despite it causing a rise in triglyceride levels which could potentially lead to further complications including inflammation of the pancreas, as well as the discontinuation of required medication for successful treatment of acute lymphoblastic leukemia.
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Journal:  A Novel Combination of High-Load Omega-3 Lysine Complex (AvailOm) and Anthocyanins Exerts Beneficial Cardiovascular Effects. (Pubmed Central) -  May 30, 2022   
    Omega-3 Ethyl Ester was identified as the main bioactive derivative of AvailOm, being capable of inducing vasorelaxant action to the same extent of entire product...These data demonstrate for the first time the direct effects of AvailOm on resistance arteries. The evidence that the combination of specific vasoactive anthocyanins and AvailOm further enhanced the vasculoprotective properties of these compounds, may offer new promising perspectives for preventing the onset of cardiovascular and cerebrovascular events.
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Trial completion, Enrollment change, Trial completion date:  Pro-Resolving Mediators in Acute Inflammation in Humans (clinicaltrials.gov) -  May 26, 2022   
    P1,  N=19, Completed, 
    The evidence that the combination of specific vasoactive anthocyanins and AvailOm further enhanced the vasculoprotective properties of these compounds, may offer new promising perspectives for preventing the onset of cardiovascular and cerebrovascular events. Recruiting --> Completed | N=48 --> 19 | Trial completion date: Dec 2022 --> Feb 2022
  • ||||||||||  Journal:  The 2021 Marine Pharmacology and Pharmaceuticals Pipeline. (Pubmed Central) -  May 14, 2022   
    In 2021, new marine-derived drugs were approved by FDA, as well as in Australia and China. The clinical development of marine-derived drugs remained very robust and active with several advancing to Ph III, Ph II and entering at Ph I.
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    New P2/3 trial:  Immunonutrition for Diabetic Foot Ulcers (clinicaltrials.gov) -  Mar 16, 2022   
    P2/3,  N=30, Not yet recruiting, 
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Trial completion date, Trial primary completion date:  Pro-Resolving Mediators in Acute Inflammation in Humans (clinicaltrials.gov) -  Mar 2, 2022   
    P1,  N=48, Recruiting, 
    The adverse effects were attenuated by treatment with Omacor, thus supporting its potential benefit and the relevance of monitoring omega-3 index in human populations at risk. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Mar 2022
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Journal:  Formation of Self-Assembled Liquid Crystalline Nanoparticles and Absorption Enhancement of Ω-3s by Phospholipids and Oleic Acids. (Pubmed Central) -  Jan 26, 2022   
    The in vitro dissolution and pharmacokinetics of Ω-3 SALCs were compared with those of Omacor soft capsules (as the reference)...We found an optimal formulation that spontaneously forms liquid crystal-based nanoparticles, improving the bioavailability of EPA and DHA, not found in the existing literature. Our findings offer insight into the impact of nanoparticle phase on the oral delivery of oil-soluble drugs and provide a novel Ω-3 EE formulation that improves the bioavailability of EPA and DHA.
  • ||||||||||  omega-3 ethylester concentrate / Generic mfg.
    Clinical, Journal:  Analysis of the impact on the health care budget and consumers of the use of the preparation of omega-3 acid ethyl esters90 in the treatment of patients with atherogenic dyslipidemia. (Pubmed Central) -  Nov 17, 2021   
    Furthermore, the difference in expenses compared to the high-dose statin treatment alone will be 359 252 253 rubles or 0.32 %.Conclusion      The results of this comprehensive pharmacoeconomical study showed that the use of omega-3 acid ethyl esters 90 in patients with residual HGT is an economically preferrable strategy compared to high-dose statin treatment alone and does not influence significantly the budgetary expenses as a part of the State Guarantee of Free Medical Care to the Citizens of the Russian Federation (increase in expenses by 0.32 % compared to the current practice). At the same time, the use of omega-3 acid ethyl esters 90 results in a 10% decrease in the number of fatal ischemic cardiovascular complications.